Reporter brief
Pilot study evaluates intravitreal sirolimus safety and vision preservation in geographic atrophy
What happened
This pilot study assessed whether intravitreal sirolimus injections are safe and can help preserve vision in patients with bilateral geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Participants aged 56 years or older with GA received sirolimus injections into one eye every 2 months over 1 year, with follow-up eye exams conducted at 8 or more visits. The abstract does not report the sample size, outcomes measured, or findings.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
People at least 56 years of age with geographic atrophy related to age-related macular degeneration in both eyes
- Design
- Other
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Jul 7, 2021
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.